AbCellera Biologics Inc.

AbCellera runs an antibody-discovery engine, it uses its platform to find and optimize therapeutic antibodies, earning milestones and royalties from drug-developer partners while building its own programs.

Ticker

ABCL

Company

AbCellera Biologics Inc.

Exchange

Nasdaq

Listing

listed

Sector

Biotech / Antibody Discovery Platform

On X, $ABCL is framed as a shovels-not-gold platform bet: you are not buying one drug, you are buying the factory that discovers many. The upside is diversified across dozens of partnered shots inside a single ticker, including programs not yet on anyone's radar.

• AbCellera Biologics is listed on Nasdaq under the ticker ABCL and files reports with the U.S. SEC.S1
• AbCellera runs an antibody-discovery platform: it finds and engineers therapeutic antibodies for drug-developer partners, earning research payments, milestones and royalties, while also advancing its own clinical programs.S2
• In fiscal year 2025 (ended December 31, 2025) AbCellera reported total revenue of about $75.1 million, up from $28.8 million in 2024, and a net loss of about $146.4 million, or $(0.49) per share.S2
• As of December 31, 2025 AbCellera reported about $561 million of total cash, cash equivalents and marketable securities, plus roughly $135 million of available non-dilutive government funding — about $700 million of total liquidity.S2
• AbCellera and its partners have advanced a cumulative total of 19 molecules into the clinic as of year-end 2025, up from 16 a year earlier.S2

• narrativePlatform-economics framing: a discovery engine spreads a clinical bet across many partnered shots, so single-readout risk matters less than for a one-asset biotech.
• narrativeBull case as it circulates: once one partnered asset de-risks the platform, the market reprices the whole engine rather than a single molecule.

• ▸AbCellera is a clinical-stage company that ran a roughly $146.4 million net loss in 2025 and depends on partner programs advancing. Clinical and regulatory execution on its own pipeline, continued cash burn and potential future dilution all apply.S2

Antibody discovery platform

— A technology stack that searches for and engineers antibodies (the proteins the immune system uses to target disease) faster and across more targets than traditional methods.

Royalty and milestone model

— Instead of selling its own drug, the company earns payments when partners hit development steps and a share of future sales.